医药价格和招采信用评价制度进一步完善 对失信行为精准加大惩戒力度

Core Viewpoint - The National Healthcare Security Administration (NHSA) has revised the medical price and procurement credit evaluation system to promote integrity and compliance in the pharmaceutical industry, aiming to foster a healthier market environment [1][2]. Group 1: Background and Implementation - In August 2020, the NHSA issued guidelines to establish a credit evaluation system based on court rulings and administrative penalties related to bribery and collusion in drug sales [1]. - By the end of 2024, a total of 735 enterprises have been rated as untrustworthy, including 7 classified as "particularly serious," 40 as "serious," 76 as "moderate," and 612 as "general" untrustworthy [1]. Group 2: Key Revisions - The revised system maintains the original framework but adjusts the evaluation levels and criteria, adding sources such as audit reports and related information [2]. - The classification of untrustworthy enterprises has been streamlined from four levels to three: "untrustworthy," "seriously untrustworthy," and "particularly seriously untrustworthy," with stricter evaluation standards [2]. - Enhanced punitive measures have been introduced, particularly for enterprises involved in bribery or collusion during centralized procurement, which will now be classified as "particularly seriously untrustworthy" [2]. - The revised procedures encourage companies to correct untrustworthy behavior through price reductions rather than relying on charitable donations [2].